As Brexit nears, Britain’s drugs, devices and pricing regulators seek the exit
Firm details on exactly how the U.K. will regulate new medicines is still to be decided after it leaves the EU later this year, but it won’t be run by Dr. Ian Hudson, who is stepping down and will be replaced by Interim CEO Dr. June Raine.
The Medicines and Healthcare products Regulatory Agency (MHRA) is the U.K.’s drug regulator, but it has worked very closely with the European Medicines Agency (EMA) for many years, as it was previously based in London. The MHRA’s role will likely change in the coming years, but for now it appears that the U.K. desires to continue following the EMA’s drug rules.
John Wilkinson, the director of devices at MHRA, will also exit after announcing his retirement.
Coincidentally, this news was announced comes on the same day that Sir Andrew Dillon, chief executive of NICE, announced his departure.
